Lun-Ling Ling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lun-Ling Ling has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Yi-Ching Wang
Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2 shared publications - Hsuan Liu
Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Guishan, Taoyuan, Taiwan, ROC
1 shared publication - Hung-Chia Hsieh
Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
1 shared publication I-Ying Kuo
Department of Biotechnology, College of Biomedical Science, Kaohsiung Medical University, Kaohsiung, Taiwan
1 shared publicationWan-Ting Kuo
Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
1 shared publication- You-En Yang
Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
1 shared publication
Latest Publications
- Open Access
- 14 January 2026
- Published by Springer Nature in Oncogenesis
- Vol. 15 (1)
Rab37-mediated OPN secretion enriches SPP1+ macrophages through autocrine–paracrine signaling to drive lung tumor progression
Tumor-associated Macrophages (TAMs) are highly plastic immune cells that shape the tumor microenvironment (TME) and influence cancer progression. However, the molecular determinants governing their functional heterogeneity remain incompletely understood. In this study, we identify Rab37 as a key regulator that remodels the states of macrophages within the lung TME. Single-cell RNA sequencing revealed that Rab37 wild-type (WT) tumors were enriched in immunosuppressive Spp1+ TAMs, whereas Rab37 knockout (KO) tumors contained a higher proportion of Thbs1+ TAMs, suggesting Rab37-dependent shifts in macrophage programming. Mechanistically, Rab37 promoted osteopontin (OPN) secretion, which activated STAT3 signaling to establish an autocrine feedback loop that sustained Spp1 expression and induced M2-like polarization. Paracrine OPN signaling further enhanced lung cancer cell proliferation, migration, and invasion. In clinical lung cancer specimens, CD163+/Rab37+/OPN+ TAMs correlated with recurrence and poor survival, and multivariate analysis confirmed their independent prognostic value. Together, these findings demonstrate that Rab37 governs macrophage phenotype and function by orchestrating OPN/STAT3 signaling, thereby reinforcing an immunosuppressive TME and promoting lung cancer progression. Targeting the Rab37-OPN axis may thus represent a promising therapeutic strategy.
- 14 January 2026
- Published by Springer Nature in Oncogenesis
- Vol. 15 (1)
Open AccessRab37-mediated OPN secretion enriches SPP1+ macrophages through autocrine–paracrine signaling to drive lung tumor progression
Tumor-associated Macrophages (TAMs) are highly plastic immune cells that shape the tumor microenvironment (TME) and influence cancer progression. However, the molecular determinants governing their functional heterogeneity remain incompletely understood. In this study, we identify Rab37 as a key regulator that remodels the states of macrophages within the lung TME. Single-cell RNA sequencing revealed that Rab37 wild-type (WT) tumors were enriched in immunosuppressive Spp1+ TAMs, whereas Rab37 knockout (KO) tumors contained a higher proportion of Thbs1+ TAMs, suggesting Rab37-dependent shifts in macrophage programming. Mechanistically, Rab37 promoted osteopontin (OPN) secretion, which activated STAT3 signaling to establish an autocrine feedback loop that sustained Spp1 expression and induced M2-like polarization. Paracrine OPN signaling further enhanced lung cancer cell proliferation, migration, and invasion. In clinical lung cancer specimens, CD163+/Rab37+/OPN+ TAMs correlated with recurrence and poor survival, and multivariate analysis confirmed their independent prognostic value. Together, these findings demonstrate that Rab37 governs macrophage phenotype and function by orchestrating OPN/STAT3 signaling, thereby reinforcing an immunosuppressive TME and promoting lung cancer progression. Targeting the Rab37-OPN axis may thus represent a promising therapeutic strategy.
- Top Cited PapersOpen Access
- 4 January 2026
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 33 (1) , 3
Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications
Immune checkpoints play pivotal roles in regulating immune responses and maintaining tolerance. In cancer, these molecules are hijacked to suppress antitumor immunity, resulting in therapeutic resistance to immune checkpoint blockade (ICB). Recent advances have highlighted the critical role of post-translational modifications (PTMs), including phosphorylation, ubiquitination, glycosylation, palmitoylation, UFMylation, acetylation, SUMOylation, methylation, and ISGylation, in modulating checkpoint stability, trafficking, and function across diverse immune and tumor cell types. These dynamic PTMs reshape the tumor microenvironment (TME) by controlling immune cell function, antigen presentation, and inflammatory signaling. This review comprehensively outlines the mechanistic contributions of PTMs to immune checkpoint regulation, emphasizing how these PTMs orchestrate immune evasion and clinical outcomes. Special focus is given to PTMs of PD-L1, PD-1, TIM-3, TIGIT, CTLA-4, LAG-3, VISTA, BTLA, and SIRPα. We also discuss how targeting PTM-regulating enzymes or specific modification motifs offers a promising therapeutic strategy to overcome ICB resistance. Understanding the PTMs landscape provides critical insight into resistance mechanisms and unveils promising opportunities for rational combination therapies aimed at reprogramming the immunosuppressive TME and enhancing antitumor immunity.
- 4 January 2026
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 33 (1) , 3
Top Cited PapersOpen AccessPost-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications
Immune checkpoints play pivotal roles in regulating immune responses and maintaining tolerance. In cancer, these molecules are hijacked to suppress antitumor immunity, resulting in therapeutic resistance to immune checkpoint blockade (ICB). Recent advances have highlighted the critical role of post-translational modifications (PTMs), including phosphorylation, ubiquitination, glycosylation, palmitoylation, UFMylation, acetylation, SUMOylation, methylation, and ISGylation, in modulating checkpoint stability, trafficking, and function across diverse immune and tumor cell types. These dynamic PTMs reshape the tumor microenvironment (TME) by controlling immune cell function, antigen presentation, and inflammatory signaling. This review comprehensively outlines the mechanistic contributions of PTMs to immune checkpoint regulation, emphasizing how these PTMs orchestrate immune evasion and clinical outcomes. Special focus is given to PTMs of PD-L1, PD-1, TIM-3, TIGIT, CTLA-4, LAG-3, VISTA, BTLA, and SIRPα. We also discuss how targeting PTM-regulating enzymes or specific modification motifs offers a promising therapeutic strategy to overcome ICB resistance. Understanding the PTMs landscape provides critical insight into resistance mechanisms and unveils promising opportunities for rational combination therapies aimed at reprogramming the immunosuppressive TME and enhancing antitumor immunity.